Skip to main content
SpringerLink
Log in

Hemmstoffe des Renin-Angiotensin-Systems

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2020

  • 2991 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Anlauf M, Weber F (2015) Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungs-Report, Bd. 2015. Springer, Berlin Heidelberg, S 267–309

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004) Empfehlungen zur Therapie der arteriellen Hypertonie, 2. Aufl. Arzneiverordnung in der Praxis, Bd. 31 (Sonderheft 2 (Therapieempfehlungen))

    Google Scholar 

  • Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M (2018) Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis 13:73. https://doi.org/10.1186/s13023-018-0815-5

    Article  PubMed  PubMed Central  Google Scholar 

  • Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators (2010) Renal outcomes with diff erent fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173–1181

    CAS  PubMed  Google Scholar 

  • Bangalore S, Kumar S, Wetterslev J, Messerli FH (2011) Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342:d2234

    PubMed  PubMed Central  Google Scholar 

  • Bangalore S, Kumar S, Messerli FH (2013) When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist? Congest Heart Fail 19:107–115

    CAS  PubMed  Google Scholar 

  • Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH (2017) Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 356:j4. https://doi.org/10.1136/bmj.j4

    Article  PubMed  PubMed Central  Google Scholar 

  • Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    CAS  PubMed  Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher Bulpitt AC, HYVET Study Group (2012) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344:1–10

    Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898

    CAS  PubMed  Google Scholar 

  • Berrido AM, Byrd JB (2020) Angiotensin receptor blockers and the risk of cancer: Insights from clinical trials and recent drug recalls. Curr Hypertens Rep. https://doi.org/10.1007/s11906-020-1021-0

    Article  PubMed  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2007) Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25:951–958

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2015) Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet 385:867–874

    Google Scholar 

  • Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2011) Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter, 1. Aufl. (Version 1.3)

    Google Scholar 

  • Byrne C, Pareek M, Vaduganathan M, Biering-Sørensen T, Qamar A, Pandey A, Olesen TB, Olsen MH, Bhatt DL (2019) Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvz050

    Article  PubMed Central  Google Scholar 

  • Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS (2014) Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol 13:91

    PubMed  PubMed Central  Google Scholar 

  • Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J (2014) Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 174:773–785

    CAS  PubMed  Google Scholar 

  • Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B (2011) The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29:4–16

    CAS  PubMed  Google Scholar 

  • Datzmann T, Fuchs S, Andree D, Hohenstein B, Schmitt J, Schindler C (2019) Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med 64:1–9

    CAS  PubMed  Google Scholar 

  • Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, the OPTIMAAL Study Group (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360:752–760

    CAS  PubMed  Google Scholar 

  • Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207

    CAS  PubMed  Google Scholar 

  • Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603–615

    PubMed  Google Scholar 

  • Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967

    PubMed  Google Scholar 

  • FDA Drug Safety Communication (2013) FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-include-intestinal-problems-sprue

  • Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355:1575–1581

    CAS  PubMed  Google Scholar 

  • Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, Melles RB, Deepak L, Bhatt DL (2019) Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med 381:243–251

    PubMed  Google Scholar 

  • Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX (2013) Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310:2544–2553

    CAS  PubMed  Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776

    CAS  PubMed  Google Scholar 

  • Hasenfuss G, Edelmann F, Wachter R (2013) Empfehlung zur Herzinsuffizienz Was gibt es Neues? Internist 54:1141–1151

    CAS  PubMed  Google Scholar 

  • Hausberg M, Trenkwalder P, Weisser B, Krämer BK (2019) Antihypertensiva: Verunsicherung durch potenziell gravierende Nebenwirkungen. Dtsch Arztebl 116:A366–A370

    Google Scholar 

  • Heerspink HL, de Zeeuw D (2010) Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 375:1140–1142

    PubMed  Google Scholar 

  • Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, Cooper M, Grobbee DE, Mancia G, Mogensen CE, Neal B, Chalmers J, ADVANCE Collaborative Group (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31:2888–2896

    PubMed  Google Scholar 

  • Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L (2018) Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 363:k4209

    PubMed  PubMed Central  Google Scholar 

  • Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D (2014) Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 167:160–168

    PubMed  Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359(23):2417–2428

    CAS  PubMed  Google Scholar 

  • Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA (2011) Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 57:174–179

    CAS  PubMed  Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031

    CAS  PubMed  Google Scholar 

  • Julius S, Nesbitt SD, Egan BM, Trial of Preventing Hypertension (TROPHY) Study Investigators (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685–1697

    CAS  PubMed  Google Scholar 

  • Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA, HEAAL Investigators (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:1840–1848

    CAS  PubMed  Google Scholar 

  • Kunz R, Friedrich C, Wolbers M, Mann JFE (2008) Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48

    PubMed  Google Scholar 

  • Lin SY, Lin CL, Lin CC, Hsu WH, Lin CD, Wang IK, Hsu CY, Kao CH (2020) Association between Angiotensin-converting enzyme inhibitors and lung cancer - A nationwide, population-based, propensity score-matched cohort study. Cancers 12(3):747. https://doi.org/10.3390/cancers12030747

    Article  CAS  PubMed Central  Google Scholar 

  • Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S, HOPE-3 Investigators (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2009–2020

    CAS  PubMed  Google Scholar 

  • Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P, PHARAO study group (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26:1487–1496

    PubMed  Google Scholar 

  • Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V (2013) Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Cmaj 185:949–957

    PubMed  PubMed Central  Google Scholar 

  • Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW (2010) Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 15:195–204

    PubMed  Google Scholar 

  • Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P, Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study (2004) Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26:855–865

    CAS  PubMed  Google Scholar 

  • Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553

    CAS  PubMed  Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    PubMed  Google Scholar 

  • McMurray JJ, Krum H, Abraham WT et al (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374:1521–1532

    CAS  PubMed  Google Scholar 

  • Messerli FH, Bangalore S, Bavishi C, Rimoldi SF (2018) Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol 71:1474–1482

    CAS  PubMed  Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006) Hypertension: management of hypertension in adults in primary care: partial update. http://guidance.nice.org.uk/CG34/guidance/pdf/English (Royal College of Physicians, London)

  • NICE guideline (2019) Hypertension in adults: diagnosis and management. www.nice.org.uk/guidance/ng136. Zugegriffen: 28. Aug. 2019

  • Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE (2013) Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310:1135–1144

    CAS  PubMed  Google Scholar 

  • Padwal R, Lin M, Etminan M, Eurich DT (2014) Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 63:977–983

    CAS  PubMed  Google Scholar 

  • Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF (2015) Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385:2047–2056

    CAS  PubMed  Google Scholar 

  • Pierre-Louis B, Rodriques S, Gorospe V, Guddati AK, Aronow WS, Ahn C, Wright M (2016) Clinical factors associated with early readmission among acutely decompensated heart failure patients. Arch Med Sci 12:538–545

    PubMed  PubMed Central  Google Scholar 

  • Pitt B (2004) ACE inhibitors for patients with vascular disease without left ventricular dysfunction – may they rest in PEACE? N Engl J Med 351:2115–2117

    CAS  PubMed  Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587

    CAS  PubMed  Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975

    PubMed  Google Scholar 

  • Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG, REACH Registry Investigators (2017) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103:1339–1346

    PubMed  Google Scholar 

  • Qiao Y, Shin JI, Teresa K, Chen TK, Inker LA, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME (2020) Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With LowEstimated Glomerular Filtration Rate. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0193

    Article  PubMed  PubMed Central  Google Scholar 

  • Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87:732–738

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951

    CAS  PubMed  Google Scholar 

  • Saglimbene V, Palmer SC, Ruospo M et al (2018) The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): a randomized, controlled trial. J Am Soc Nephrol 29:2890–2899

    PubMed  PubMed Central  Google Scholar 

  • Sanchis-Gomar F, Carl J, Lavie CJ, Perez-Quilis C, Brandon MH, Lippi G (2020) Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Proc. https://doi.org/10.1016/j.mayocp.2020.03.026

    Article  Google Scholar 

  • Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E, SCAST Study Group (2011) The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377:741–750

    CAS  PubMed  Google Scholar 

  • Sato A, Fukuda S (2015) A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens 37:563–568

    CAS  PubMed  Google Scholar 

  • Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sorensen HT (2015) Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol 29:1545–1554

    CAS  PubMed  Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007) Renin angiotensin system and cardiovascular risk. Lancet 369:1208–1219

    CAS  PubMed  Google Scholar 

  • Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299–2307

    PubMed  Google Scholar 

  • Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group (2003) The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 234:1699–1703

    Google Scholar 

  • Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218–1226

    CAS  PubMed  Google Scholar 

  • Smith L, Parris C, Veronese N, Shang C, Lopez-Sanchez GF, Jacob L, Koyanagi A, Nottegar A, Jackson SE, Raupach T, Grabovac I, Crichton S, Dempsey F, Yang L (2020) Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults. Clin Exp Med. https://doi.org/10.1007/s10238-020-00622-7

    Article  PubMed  Google Scholar 

  • Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, Paragon-Hf Investigators Committees (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620

    CAS  PubMed  Google Scholar 

  • Staessen JA, Li Y, Thijs L, Wang JG (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28:385–407

    PubMed  Google Scholar 

  • Stiles S (2018) Old Age and ACE inhibitors in heart failure: cohort study tries to bridge guidelines gap – Medscape

    Google Scholar 

  • Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB (2019) Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 394:1816–1826

    PubMed  PubMed Central  Google Scholar 

  • Svensson P, de Faire U, Sleight P, Yusuf S, Östergren JJ (2001) Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38:e28–e32

    CAS  PubMed  Google Scholar 

  • Tamargo J (2019) Sodium–glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments. Eur Cardiol Rev 14:23–32

    Google Scholar 

  • The ACTIVE I Investigators (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938

    Google Scholar 

  • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788

    Google Scholar 

  • The GISSI-AF Investigators (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617

    Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153

    Google Scholar 

  • The ONTARGET Investigators (2008) Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Google Scholar 

  • The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens 36:1953–2041

    Google Scholar 

  • The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183

    Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2017a) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. J Hypertens 35:2138–2149

    CAS  PubMed  Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2017b) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944

    CAS  PubMed  Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2017c) Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 35:2150–2160

    CAS  PubMed  Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2018a) Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 – benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. J Hypertens 36:1622–1636

    CAS  PubMed  Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2018b) Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 – effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens 36:1637–1647

    CAS  PubMed  Google Scholar 

  • Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA (2011) Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305:913–922

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tsimploulis A, Lam PH, Arundel C, Singh SN, Morgan CJ, Faselis C, Deedwania P, Butler J, Aronow WS, Yancy CW, Fonarow GC, Ahmed A (2018) Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction. JAMA Cardiol 3:288–297

    PubMed  PubMed Central  Google Scholar 

  • Verma S, Strauss M (2004) Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction – and patients may need to be told. BMJ 329:1248–1249

    PubMed  PubMed Central  Google Scholar 

  • Vidal-Petiot E, Sorbets E, Bhatt DL et al (2018) Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. Eur Heart J 39:3855–3863

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB (2005a) Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:705–711

    PubMed  Google Scholar 

  • Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005b) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712–719

    CAS  PubMed  Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334

    CAS  PubMed  Google Scholar 

  • Weber F, Anlauf M (2019) Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (Hrsg) Arzneiverordnungs-Report. Springer, Berlin, Heidelberg, S 359–388

    Google Scholar 

  • Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013) Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381:537–545

    PubMed  Google Scholar 

  • Whelton PK, Carey RM (2018) The 2017 American College of Cardiology/American Heart Association Clinical Practice Guideline for high blood pressure in adults. JAMA Cardiol 3:352–353

    PubMed  Google Scholar 

  • Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM, SPRINT Research Group (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 315:2673–2682

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70:776–803

    PubMed  Google Scholar 

  • Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, Li Y, Wang H, Chen L, Wu M, Zhao H (2016) Drug interactions with angiotensin receptor blockers: role of human cytochromes P450. Curr Drug Metab 17:681–691

    CAS  PubMed  Google Scholar 

  • Yusuf S (2002) From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89:18A–25A

    PubMed  Google Scholar 

  • Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S for the PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359:1225–1237

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thiemannstraße 18, 45219, Essen, Deutschland

    Prof. Dr. med. Franz Weber

  2. Friedrich-Plettke-Weg 12, 27570, Bremerhaven, Deutschland

    Prof. Dr. med. Manfred Anlauf

Authors
  1. Prof. Dr. med. Franz Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franz Weber .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Weber, F., Anlauf, M. (2020). Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62168-4_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62167-7

  • Online ISBN: 978-3-662-62168-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation